Eli Lilly and Company Transparent Logo - Search News

Insider Monkey on MSN · 1d

Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest In

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other counter cyclical and defensive stocks to invest in.

MarketWatch · 14d

Eli Lilly & Co. stock underperforms Thursday when compared to competitors

Shares of Eli Lilly & Co. LLY shed 3.55% to $912.75 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.30% to 5,503.41 and Dow Jones Industrial Average DJIA falling 0.

Zacks.com on MSN · 3d

Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month,

Insider Monkey on MSN · 3d

Eli Lilly and Company (LLY): Among Morgan Stanley’s Best Stock Picks for 2025

We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Morgan Stanley’s other stock picks.

17h

Lilly Wants Records of People Who Took Weight-Loss Knockoffs

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

7d

Eli Lilly & Co. stock outperforms competitors on strong trading day

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

14d

Eli Lilly bets $409M for AI-focused drug discovery

Eli Lilly (LLY) partners with Genetic Leap to develop gene-based therapeutics using AI-driven drug discovery, in a deal worth ...

FierceBiotech11d

With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave

He is now chairman, president and CEO of Candid Therapeutics, which has debuted with a $370 million series A and a goal to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results